Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: zofran Clear all
Completed Phase 3 Interventional

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

NCT00334152
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting
Interventions
casopitant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
25
States / cities
Fairhope, Alabama • Mobile, Alabama • Montgomery, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

New Medication Treatment for Stimulant Dependence

NCT00689572
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

NCT00648583
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron Tablets 24 mg, Zofran® Tablets 24 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

NCT02246439
View directory record Official record
Conditions
Gastroenteritis, Gastritis
Interventions
RHB-102, Placebo Oral Tablet
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
12 Years to 85 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
26
States / cities
Bakersfield, California • Sacramento, California • Sylmar, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 9, 2026, 12:45 PM EDT
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 4 Interventional

Uncomplicated Nausea and Vomiting in the Emergency Department

NCT00778011
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Metoclopramide
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 9, 2026, 12:45 PM EDT
Not listed Phase 2Phase 3 Interventional

Opioid Free Anesthesia vs. Opioid Anesthesia Techniques.

NCT03367988
View directory record Official record
Conditions
Analgesic Drug Dependence, Colectomy
Interventions
Opioid Anesthesia, Opioid-free Anesthesia
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Not applicable Interventional

Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy

NCT00005994
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ondansetron
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
4
States / cities
Hackensack, New Jersey • Rochester, New York • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 9, 2026, 12:45 PM EDT
Recruiting Not applicable Interventional

ERAS Protocols in Breast Conserving Surgery

NCT06938581
View directory record Official record
Conditions
Breast Cancer, Postoperative Recovery
Interventions
ERAS Protocol, Standard Perioperative Care
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

NCT00598507
View directory record Official record
Conditions
Melanoma
Interventions
ZK-EPO
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

NCT01474915
View directory record Official record
Conditions
Postoperative Nausea and Vomiting (PONV), Nausea
Interventions
Aprepitant, Ondansetron, Promethazine, Dexamethasone
Drug
Lead sponsor
Sergio Bergese
Other
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Not applicable Interventional Results available

Emergency Department (ED) Drug Interaction in Emergency Department Patients

NCT01859715
View directory record Official record
Conditions
Drug Interactions
Interventions
Oxycodone, Hydrocodone, Ondansetron
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 95 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Not applicable Interventional Results available

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

NCT01549652
View directory record Official record
Conditions
Opioid Withdrawal, Physical Dependence
Interventions
Ondansetron, Placebo, Morphine, Naloxone 0.4 mg/70 kg, Naloxone 0.8 mg/70 kg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 9, 2026, 12:45 PM EDT
Terminated Phase 3 Interventional Results available

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 4 Interventional Results available

Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy

NCT00734929
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant + Dexamethasone, Ondansetron + Dexamethasone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

NCT01319565
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Not applicable Interventional

ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment

NCT02610517
View directory record Official record
Conditions
HIV, Alcoholism
Interventions
Provider Training, Patient Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Results available

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

NCT03030417
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 3 Interventional

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

NCT00020657
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dolasetron mesylate, granisetron hydrochloride, ondansetron, prochlorperazine, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Emend for Multiple-day Emetogenic Chemotherapy

NCT00711555
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
aprepitant, ondansetron, dexamethasone
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 9, 2026, 12:45 PM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Early Phase 1 Interventional

Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)

NCT03125811
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Inhaled Isopropyl Alcohol (IPA), Oral Dissolvable Tablet Zofran (ondansetron)
Other · Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 9, 2026, 12:45 PM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

NCT01335542
View directory record Official record
Conditions
Readiness to Discharge
Interventions
Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 9, 2026, 12:45 PM EDT